His clinical and research work is focused on improving therapies for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). His primary commitment is to bring new agents/combinations to the clinic for improving outcome in patients with these diseases. He has particular interest in core binding factor leukemia. He has opened more than thirty investigator-initiated or industry-sponsored clinical trials in his area of interest and has an active translational research program on autophagy , mitochondrial dynamics, kinase inhibition (ERK 1/2) and epigenetic targets, for example BRD4 in AML.